BLUE BELL, Pa., Nov 12, 2010 (BUSINESS WIRE) -- Inovio Pharmaceuticals, Inc.
(NYSE Amex:INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that Dr.
Spyros Kalams will provide an update of interim immune responses and safety results from the HVTN 080 Phase I clinical study of Inovio's PENNVAX(TM)-B HIV DNA vaccine in a preventive setting. Dr. Kalams, principal investigator of this clinical study, is Immunology Director of the Vanderbilt Center for AIDS Research at Vanderbilt University Medical Center, and Associate Professor of Medicine and Associate Professor of Microbiology and Immunology at Vanderbilt University. The multi-center study is being conducted by Inovio's clinical collaborator, the HIV Vaccine Trials Network (HVTN), at several clinical sites and is sponsored by the Division of AIDS (DAIDS) of the National Institute of Allergy and Infectious Diseases (NIAID), an agency of the National Institutes of Health (NIH).
Presentation details: Wed., November 17th 8:30 - 9:30 am Plenary Session 7: HVTN Data Updates 8:45 - 9:00 Dr. Spyros Kalams: HVTN 080 PENNVAX-B is being tested under a protocol designated HVTN-080. Inovio previously announced the completion of enrollment of 48 healthy volunteers.
Inovio previously reported data from non-human primates demonstrating up to a 100-fold enhancement in immune responses resulting from the vaccine when delivered via in vivo electroporation compared to syringe injection without electroporation. The HVTN-080 study is assessing safety and levels of immune responses in humans.
About Inovio Pharmaceuticals, Inc.
Inovio is developing a new generation of vaccines, called DNA vaccines, to treat and prevent cancers and infectious diseases. These SynCon(TM) vaccines are designed to provide broad cross-strain protection against known as well as newly emergent strains of pathogens such as influenza. These vaccines, in combination with Inovio's proprietary electroporation delivery devices, have been shown to be safe and generate significant immune responses. Inovio's clinical programs include HPV/cervical dysplasia and cancer (therapeutic), avian flu (preventive), and HIV vaccines (both preventive and therapeutic). Inovio is developing universal influenza and other vaccines in collaboration with scientists from the University of Pennsylvania. Other partners and collaborators include Merck, National Cancer Institute, U.S. Military HIV Research Program, HIV Vaccines Trial Network, National Microbiology Laboratory of the Public Health Agency of Canada, and PATH Malaria Vaccine Initiative. More information is available at www.inovio.com.
This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, our ability to successfully integrate Inovio and VGX Pharmaceuticals, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2009, our Form 10-Q for the six months ended June 30, 2010, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.
SOURCE: Inovio Pharmaceuticals, Inc.
CONTACT: Investors: Inovio Pharmaceuticals Bernie Hertel, 858-410-3101 email@example.com or Media: Richardson & Associates Jeff Richardson, 805-491-8313 firstname.lastname@example.org Copyright Business Wire 2010 -0- KEYWORD: United States
Pennsylvania INDUSTRY KEYWORD: Health
Pharmaceutical SUBJECT CODE: Conference